

1 **High glycaemic variability in individuals with type 1 diabetes is associated**
2 **with a reduced proportion of CD8⁺ TNF⁺ cells in response to influenza A virus**

3 Marcus Tong Zhen Wei^{1*}, Katina D. Hulme^{1,2*}, Soi Cheng Law³, Ellesandra Noye¹, Emily S. Dorey³, Keng Yih
4 Chew¹, , Louise C. Rowntree⁵, Carolien E. van de Sandt^{5,6}, Katherine Kedzierska⁵, Marco Goeijenbier^{8,9},
5 Katharina Ronacher^{3,7}, Fawaz Alzaid^{10,11}, Jean-Baptiste Julla^{10,12}, Jean-Pierre Riveline^{10,12}, Katie Lineburg¹³,
6 Corey Smith^{13,14}, Emma J. Grant^{15,16}, Stephanie Gras^{15,16}, Linda A. Gallo¹⁷, Helen L. Baret^{3, 18,19}, Kirsty R.
7 Short^{1,7,14+}

8 **Affiliations:**

- 9 1. *School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia*
10 2. *Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam,*
11 *Netherlands*
12 3. *Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia*
13 5. *Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for*
14 *Infection and Immunity, Melbourne, VIC, Australia*
15 6. *Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University*
16 *of Amsterdam, Amsterdam, The Netherlands*
17 7. *Australian Infectious Diseases Research Centre, The University of Queensland, St Lucia, Australia*
18 8. *Department of intensive care, Erasmus MC, Rotterdam, The Netherlands*
19 9. *Department of intensive care, Spaarne Gasthuis, Haarlem/Hoofddorp, The Netherlands*
20 10. *Université Paris Cité, CNRS, INSERM, Institut Necker Enfants Malades-INEM, F-75015 Paris, France*
21 11. *Dasman Diabetes Institute, Kuwait, Kuwait*
22 12. *Department of Diabetes, Clinical Investigation Centre (CIC-9504), Lariboisière Hospital, Assistance Publique*
23 *- Hôpitaux de Paris, Paris, France*
24 13. *QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia*
25 14. *Queensland Immunology Research Centre, St Lucia, Australia*
26 15. *Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, Bundoora, Australia*
27 16. *Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Clayton,*
28 *Australia*
29 17. *School of Health and Behavioural Sciences, University of the Sunshine Coast, Petrie, Australia*
30 18. *University of New South Wales Medicine, Kensington, Australia*
31 19. *Obstetric Medicine, Royal Hospital for Women, Randwick, Australia*

32
33 * These authors contributed equally to this study

34 + email: k.short@uq.edu.au

35

36

37

38

39

40

41

42

43

44 **ABSTACT:**

45 *Objective:* Diabetes mellitus significantly increases the risk of severe respiratory virus disease like
46 influenza and COVID-19. Early evidence suggests that this susceptibility to respiratory viral disease is
47 driven by glycaemic variability, rather than average blood glucose levels. In healthy individuals,
48 blood glucose levels remain relatively stable throughout the day. However, in individuals living with
49 diabetes, blood glucose spikes are more frequent and higher in magnitude. Continuous glucose
50 monitoring (CGM) provides a unique opportunity to detect these hyper and hypoglycaemic events,
51 even in the presence of an in range HbA1c.

52 *Research design and methods:* Here, we use blood samples and CGM data obtained from people
53 living with Type 1 diabetes (T1D) to determine the effects of glycaemic variability on the T-cell
54 response to influenza virus. Low glycaemic variability was defined as a coefficient of variation (CV)
55 <33% (n = 13) whilst high glycaemic variability was defined as a CV \geq 33% (n = 19).

56 *Results:* We show that high glycaemic variability in participants living with T1D is associated with a
57 reduced proportion of CD8⁺CD107 α ⁻IFN γ ⁻MIP1 β ⁻TNF⁺ T-cells in response to stimulation with
58 influenza virus and an influenza peptide pool. High glycaemic variability in this patient population is
59 primarily driven by hypoglycaemic events and was also associated with an increase in the proportion
60 of naïve CD8⁺ T cells and a decrease in terminally differentiated CD8⁺ T cells (T_{EMRA}).

61 *Conclusions:* Together, this study provides the first evidence that glycaemic variability affects the T-
62 cell response to respiratory viruses. These data suggest that monitoring glycaemic variability may
63 have important implications in understanding the antiviral immune response in people with diabetes.

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80 **INTRODUCTION:**

81 Diabetes mellitus (both type 1 [T1D] and type 2 [T2D]) significantly increases the risk of severe
82 respiratory virus infections¹⁻⁴. The mechanisms by which this occurs remain poorly defined.
83 Hyperglycaemia (high blood glucose levels) is typical of both T1D and T2D and its persistence is
84 indicated by elevated glycated haemoglobin (HbA1C) levels. Hyperglycaemia is associated with
85 increased susceptibility to severe disease, including respiratory tract infections. A meta-analysis
86 showed that chronic hyperglycaemia (HbA1c levels $\geq 7.0\%$) is associated with at least a 2.5 fold
87 increased risk of pulmonary tuberculosis relative to patients with lower ($< 7.0\%$) HbA1c levels⁵.
88 Hyperglycaemia (relative to in range blood glucose levels) also significantly increased the risk of
89 mortality, ICU admission and intubation for COVID-19 in patients with T2D⁶. Similarly, *in vitro* high
90 glucose levels increase pulmonary epithelial-endothelial damage from influenza virus infection⁷. An
91 elevated HbA1C in patients with diabetes is also associated with impaired TNF production by CD8⁺ T
92 cells⁸.

93 In contrast to consistently high average blood glucose levels there is now a growing body of evidence
94 that glycaemic variability may also play a significant role in susceptibility to severe respiratory virus
95 infections^{4,9-13}. Typically, in healthy individuals blood glucose levels remain relatively stable
96 throughout the day except for small and short-lived post-prandial peaks. However, in individuals
97 living with diabetes these postprandial glucose spikes are more frequent and higher in magnitude.
98 This glycaemic variability is not indicated in measurements of a patient's HbA1c, which largely
99 reflects a 3-month average of blood glucose levels in terms of the percentage of glycated
100 haemoglobin. Instead, blood glucose variability can be detected using continuous glucose monitors
101 (CGM). Indeed, CGM data has shown that both T1D patients and T2D patients experience significant
102 fluctuations in blood glucose levels over time^{14,15}. In contrast, healthy individuals with CGM data
103 display minimal, if any, out of range fluctuations¹⁶. Several studies have shown that glycaemic
104 variability increases the severity of COVID-19^{4,11-13} and there is evidence that a similar phenomenon
105 occurs with influenza virus⁹. However, such studies typically depend on successive measurements of
106 an individual's blood glucose levels (rather than CGM data) and the mechanisms underlying this
107 association remains to be determined.

108 Here, we hypothesise that high glycaemic variability (as determined by CGM data) reduces the anti-
109 viral immune response to influenza virus.

110

111

112

113

114

115

116

117

118

119

120

121 **MATERIALS AND METHODS:**

122 **Influenza virus culture**

123 Virus stocks of HKx31 (H3N2) were prepared in embryonated chicken eggs and titres of infectious
124 virus were determined by plaque assays on MDCK cells as previously described¹⁷. The use of
125 embryonated chicken eggs was approved by the University of Queensland Animal Ethics Committee
126 (AE000089).

127 **Participant recruitment**

128 A cohort of 32 people with clinically diagnosed T1D who were routinely using continuous, or flash
129 glucose monitoring (CGM) devices were recruited in Brisbane, Australia between 8/6/21 and
130 11/11/21. These individuals were a subset of a previously described cohort of 72 patients with
131 diabetes mellitus (T1D and T2D)¹⁸. Inclusion criteria were 18-60 years of age, not pregnant at the
132 time of study, non-smokers of nicotine cigarettes, minimum diabetes mellitus duration of two years
133 and no known immune disease requiring immunosuppressants. Blood, clinical data, and two weeks
134 of prior CGM data from these participants were collected at the point of recruitment. To further
135 establish the quality of CGM data, only samples with CGM time worn above 70% were included in
136 the analysis. This study was approved by Mater Research Ethics Committee (HREC/MML/55151 V2)
137 and the University of Queensland Ethics Committee (2019/HE002522). All methods were performed
138 in accordance with institutional guidelines and regulations. Written consent was obtained from all
139 study participants.

140 **Glycaemic variability**

141 Glycaemic variability was determined based on an individual's coefficient of variation (CV; glucose
142 SD expressed as a percentage of the mean glucose) reading from their CGM with the threshold set at
143 33.0% as described previously¹⁹.

144 **Human PBMC isolation**

145 10mL of whole peripheral blood was collected in BD Vacutainer® EDTA tubes (BD Biosciences).
146 Peripheral blood mononuclear cells (PBMC) were isolated with Lymphoprep (STEMCELL, Canada)
147 according to manufacturer's instructions. Isolated PBMC were subsequently frozen down in Fetal
148 Calf Serum (FCS) (Gibco) containing 10% DMSO (Sigma-Aldrich) at -80 °C until analysis.

149 **Human T-cell phenotype characterisation**

150 To study the effects of glycaemic variability on CD8⁺ T-cell phenotypic markers, PBMCs isolated from
151 participants were stained as previously described²⁰. Briefly, T-cells were washed and stained for
152 lymphocyte (anti-CD3; anti-CD4 anti-CD8) and differentiation markers (anti-CD27, anti-CD45RA and
153 anti-CD95) ([Key Resource Table](#)). T-cells were subsequently washed and fixed. All samples were
154 analysed on LSRFortessa (BD Biosciences) and analysed using FlowJo v10.8 (BD Biosciences). Gating
155 was performed as previously described⁸.

156 **T-cell stimulation and intracellular cytokine staining (ICS) on human PBMC**

157 To investigate the effect of glycaemic variability on the cytokine response of T-cells *ex vivo*, PBMCs
158 from each donor were stimulated with either i) HKx31 (multiplicity of infection 10), ii) 25ng/mL
159 phorbol myristate acetate and 1µg/mL Ionomycin (PMA/I Sigma Aldrich) iii) CD3/CD28 magnetic
160 beads (Thermo Fisher; Dynabeads) or iii) influenza virus peptide pool (4µg/mL; AnaSpec)
161 ([Supplementary Table 1](#)) in RPMI1640 (Gibco) with 10% FCS (Gibco) as described previously⁸.

162 Stimulations were performed for 18 hours (influenza virus, influenza virus peptide pool) in the
163 presence of anti-CD107a (0.4µg/mL; BioLegend; H4A3), BD GolgiStop and BD GolgiPlug (BD
164 Biosciences). T-cells were subsequently washed and stained for anti-CD3, CD4 and CD8 (**Key
165 Resource Table**). T-cells were then washed, fixed, and permeabilised using the BD Cytfix/Cytoperm
166 Fixation/Permeabilization kit (BD Biosciences) and stained with anti-MIP1β, anti-IFNγ and anti-TNF
167 (**Key Resource Table**). Cells were analysed on the LSRFortessa (BD Biosciences) and analysed using
168 FlowJo v10.8 (BD Biosciences). To assess the functionality of these T-cells, the number of MIP-1β+,
169 IFNγ+, TNF+ and CD107a+ cells were assessed according to our previously described gating strategy⁸.

170 **Statistical analysis**

171 Statistical analyses were performed with GraphPad Prism software (version 9.3.1) (Dotmatics, CA,
172 USA). After determining the normality of distribution with Shapiro-Wilk normality test, outliers
173 within data sets were removed according to the ROUT (1%) test. Continuous data were tested for
174 statistical significance with a Mann-Whitney test or t-test as appropriate. Categorical data were
175 tested for statistical significance with a chi-square test. Multiple linear regression was performed
176 with R software version 4.1.1 (The R Project).

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198 **RESULTS:**

199 To investigate the effect of glycaemic variability on anti-viral T-cell populations, 32 participants with
 200 T1D were recruited. These participants all had at least two weeks of CGM data available for analysis.
 201 Using a CV threshold of 33%, participants were classified as having either low (n = 13) or high (n = 19)
 202 glycaemic variability. Participants with low and high glycaemic variability were of equivalent age, sex
 203 distribution, type of insulin treatment (injection/pump), body mass index (BMI) and had a similar
 204 duration of diabetes (approximately 15 years; [Table 1](#)) and recent history of influenza virus infection.
 205 Importantly, participants with low and high glycaemic variability had equivalent HbA1c levels and
 206 blood glucose levels at the time of sample collection ([Table 1](#)). The high glycaemic variability group
 207 had a lower rate of influenza virus vaccination within the last 6 months ([Table 1](#)). Patients reported
 208 taking several other medications besides from those associated with diabetes management, the most
 209 common of which was some form of contraception ([Supplementary Table 2](#)).
 210


211 **Table 1: Participant characteristics using a threshold of 33% CV¹**

	Low glycaemic variability (n = 13)	High glycaemic variability (n = 19)	P value ²
	Mean (SD)	Mean (SD)	
Age (years)	29.88 (±11.69)	26.49 (±6.67)	0.6172
Sex (male;female)	4;9	6;13	0.5993
BMI (kg/m ²)	26.33 (±4.79)	26.45 (±4.94)	>0.9999
HbA1c (%)	7.92 (±1.75)	7.75 (±1.42)	0.5505
Diabetes duration (years)	14.54 (±9.12)	15.15 (±5.24)	0.6151
Average blood glucose (mmol/L) ³	11.83 (±3.54)	9.83 (±2.65)	0.0823
CV (%)	27.01 (±4.32)	39.15 (±3.25)	<0.0001 (*)
Type of insulin treatment (injection;pump) ⁴	4;9	9;10	0.3477
Time in range	38.38 (±28)	56.95 (20.85)	0.04(*)
Influenza virus vaccination (Y;N)	10;3	5;14	0.0048 (*)
Recent respiratory virus infection (Y;N)	0;13	0;19	-

212 1. Abbreviations: BMI body-mass index, HbA1c glycated haemoglobin Type A1C, CGM continuous glucose
 213 monitor, CV coefficient of variation. Participants were grouped based on their CV% from CGM data, threshold
 214 set at 33%. 2. P-value was determined wither either Mann-Whitney test (age, BMI, diabetes duration, average
 215 glucose), a t-test (time in range) or chi-square test at a 0.05 significance level (sex, type of insulin treatment,
 216 influenza virus vaccination history, SARS-CoV-2 vaccination). 3. Average blood glucose levels were recorded as
 217 an average of all glucose readings across time worn. 4. Insulin regime (basal vs. bolus, long lasting vs fast
 218 acting insulin) was not recorded. 5. 12/13 individuals received two vaccine doses; 1 individual only received

219 one 6. All individuals received two vaccine doses with the exception of one individual for whom data was not
220 available.

221 To demonstrate the glycaemic profile in high and low glycaemic variability, representative CGM data
222 from each group is shown in Fig. 1A. To evaluate the differences in glycaemic profile between low
223 glycaemic variability and high glycaemic variability with a CV threshold at 33%, the time glucose
224 levels were above and below the healthy range (3.9mmol/L – 10.0mmol/L) were assessed (Fig. 1B).
225 Participants with high glycaemic variability had significantly lesser time spent with hyperglycaemic
226 levels, but significantly higher time spent with hypoglycaemic levels (Figure 1B).



227

228 **Figure 1. Higher time recorded with hypoglycaemic levels were observed in participants with high**
229 **glycaemic variability (GV).** (A). Representative CGM data for individuals with low glycaemic
230 variability and high glycaemic variability (B). The difference in time glucose levels spent above and
231 below the glycaemic healthy range (3.9mmol/L to 10.0mmol/L) were analysed between both groups.
232 Statistical significance was assessed as described in the Materials and Methods. $P < 0.05$ *; $P < 0.001$
233 ***

234 To characterise the T-cell populations of both participant groups the percentage of circulating $CD4^+$
235 and $CD8^+$ T-cells were assessed. There was no significant difference in the percentage of $CD4^+$, $CD8^+$,
236 the ratio of $CD4:CD8$ cells or $CD4^+CD8^-$ T-cells between those with low glycaemic variability and high
237 glycaemic variability (Fig. 2A). To better define the subsets of $CD4^+$ and $CD8^+$ T-cells the percentage
238 of circulating naïve T-cells ($T_{naïve}$; $CD27^+CD45RA^+CD95^-$), stem cell memory T-cells (T_{SCM} ;
239 $CD27^+CD45RA^+CD95^+$), central memory T-cells (T_{CM} ; $CD27^+CD45RA^-$), effector memory T-cells (T_{EM} ;
240 $CD27^-CD45RA^-$) and effector memory re-expressing $CD45RA$ T-cells (T_{EMRA} ; $CD27^-CD45RA^+$) of the

241 total CD4⁺ and CD8⁺ T-cell populations were established (Fig. 2B). No significant differences were
242 seen in the CD4⁺ T-cell subsets between the two participant groups (Fig. 2B). In contrast, patients
243 with high glycaemic variability had a significantly higher percentage of T_{naive} CD8⁺ T-cells but a
244 significantly lower percentage of T_{EMRA} CD8⁺ T-cells compared to patients with low glycaemic
245 variability (Fig. 2B).

246 Next, the cytokine response of T-cells to *ex vivo* stimulation with infectious influenza virus was
247 assessed (Fig. 2C). In terms of CD4⁺ T-cells, a lower proportion of CD107a⁺IFN γ ⁻MIB1b⁺TNF⁺,
248 CD107a⁺IFN γ ⁻MIB1b⁻TNF⁺ and CD107a⁻IFN γ ⁻MIB1b⁻TNF⁺ cells were observed in individuals with high
249 GV. In terms of CD8⁺ T-cells, a lower proportion of CD107a⁺IFN γ ⁻MIB1b⁺TNF⁺, CD107a⁻IFN γ ⁺MIB1b⁻
250 TNF⁻ and CD107a⁻IFN γ ⁻MIB1b⁻TNF⁺ cells were observed in individuals with high GV (Fig. 2C). We then
251 sought to validate these observations in CD8⁺ T-cells stimulated with an influenza virus peptide pool
252 (Fig. 2D). Consistent with the observations using infectious virus, low glycaemic variability samples
253 treated with influenza virus peptide pool had a significantly higher proportion of CD8⁺CD107a⁺IFN γ ⁻
254 MIP1 β ⁺TNF⁺ relative to healthy controls and high glycaemic variability samples (Fig. 2D). Also
255 consistent with our infectious influenza virus stimulations, high glycaemic variability samples
256 stimulated with influenza peptides had a significantly lower proportion of CD8⁺CD107a⁻IFN γ ⁻MIP1b⁻
257 TNF⁺ T-cells compared to low glycaemic variability samples (Fig. 2D). When the proportion of any
258 CD8⁺TNF⁺ cell after IAV or IAV peptide pool stimulation was examined significantly higher
259 proportions were still observed in low glycaemic variability samples (Supplementary Fig. 1). Given
260 that a decreased proportion of CD8⁺CD107a⁻IFN γ ⁻MIP1b⁻TNF⁺ cells in high glycaemic variability
261 samples were consistently observed between influenza virus and influenza peptide pool stimulations
262 and showed the largest difference relative to low glycaemic variability samples, we elected to focus
263 on this population.

264

265 We next sought to determine if individuals with high glycaemic variability continued to display a
266 decreased proportion of CD8⁺CD107a⁻IFN γ ⁻MIP1 β ⁺TNF⁺ cells in response to non-specific stimuli like
267 PMA/I and Dynabeads (CD3/CD28) (Fig. 2E & F). Interestingly, unlike influenza virus stimulations,
268 there were several incidences of CD4⁺ and CD8⁺ T-cell populations being higher in individuals with
269 high glycaemic variability following this non-specific stimulation. Furthermore, unlike influenza virus
270 stimulations, there was no significant difference in the proportion of CD8⁺CD107a⁻IFN γ ⁻MIP1 β ⁺TNF⁺
271 between healthy donors, those with high glycaemic variability and those with low glycaemic
272 variability in response to either PMA/I (Fig. 2E) or Dynabeads (Fig. 2F). Taken together, these data
273 suggest that the observed phenotype may be specific to influenza virus or perhaps more broadly
274 viral peptides.


275 One limitation of these analyses is that some of the observed changes to influenza virus stimulation
276 may be the result of a differential influenza virus vaccination history between those with low and
277 high glycaemic variability (Table 1), although as an inactivated subunit vaccine vaccination does not
278 typically induce strong cellular immunity. Nevertheless, we investigated the *ex vivo* CD8⁺ T-cell
279 response follow influenza virus stimulation exclusively in influenza vaccinated individuals. Consistent
280 with our original observations influenza vaccinated individuals with low glycaemic variability had a
281 higher proportion of CD8⁺CD107a⁺IFN γ ⁻MIP1 β ⁺TNF⁺ cells (Supplementary Fig. 2). Furthermore, those
282 with low glycaemic variability had a trend towards an increased percentage of CD8⁺ CD107a⁻IFN γ ⁻
283 MIP-1 β ⁺TNF⁺ T-cells (p = 0.05; Supplementary Fig. 2). This held true when the proportion of any
284 CD8⁺TNF⁺ cell after IAV stimulation was examined (Supplementary Fig. 2). To further complement
285 these results, we performed a multiple linear regression model looking at the relationship between
286 glycaemic variability, influenza vaccination status and the percentage of CD8⁺CD107a⁻IFN γ ⁻MIP-1 β ⁺

287 TNF⁺ T-cells. Importantly glycaemic variability (high vs low) had a significant relationship with the
288 percentage of CD8⁺ CD107a⁻IFN γ ⁻MIP-1 β ⁻TNF⁺ (p = 0.04) T-cells whilst influenza vaccination did not
289 (p = 0.350).

290

291

292



294 **Fig. 2. Participants with higher glycaemic variability (GV) exhibit an altered T-cell**
295 **profile and proportion of TNF α + cells in response to influenza virus stimulation.**
296 PBMC from participants were stained for CD4 and CD8. CD4⁺, CD4⁺CD8⁻ and CD8⁺ positive
297 T-cells (**A**) were stained for CD27, CD45RA and CD95 to further define T-cell subsets (**B**).
298 To study T cell function, Boolean gating analysis was used. PBMC were stimulated with
299 HKx31 (MOI10) (**C**) influenza virus peptide pool (**D**) PMA/I (**E**) and Dynabeads (**F**) for 18
300 hours. PBMC were then stained for CD107a, IFN γ , MIP-1 β and TNF. Statistical significance
301 was determined as described in the Materials and Methods. Bars and error bars represent
302 means (\pm SEM). Gating was performed as previously described¹⁰. *: p<0.05.

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329 **DISCUSSION:**

330 Individuals with diabetes can experience significant intra and inter-day fluctuations in blood glucose
331 levels. To date, the effect of these fluctuations on the T-cell response to influenza virus, or other
332 viral diseases, has been undefined. Here, we provide the show that this glycaemic variability is
333 associated with changes in the T-cell population and reduced CD8⁺ T cell TNF production to *ex vivo*
334 stimulation with influenza virus.

335 Patients with high glycaemic variability had a significantly higher percentage of T_{naive} CD8⁺ T-cells
336 compared to patients with low glycaemic variability. Considering the clinical evidence that high
337 glycaemic variability is associated with more severe viral disease^{4,9-13} it is interesting to speculate
338 what functional consequences increased T_{naive} CD8⁺ T-cell population may have. Whether this
339 represents a population of T-cells that is unable to differentiate into functional effector or memory
340 cells (which would then likely be associated with an impaired immune response) remains to be
341 determined. Therefore, the clinical consequences of these observations, if any, require further
342 investigation.

343 In the present study we observed a reduced proportion of CD8+CD107α-IFNγ-MIP1β-TNF+ T-cells in
344 response to stimulation with influenza virus. This same phenomenon was not observed following
345 stimulation with non-specific stimuli (such as PMA/I or Dynabeads). This suggests that high
346 glycaemic variability does not impair CD8+ T cell function *per se* rather more specifically the
347 response to influenza virus or viral stimulation. The production of TNF by CD8+ T cells during a viral
348 infection is essential for the induction of apoptosis, the recruitment and activation of other immune
349 cells, CD8+ T-cell function and the regulation of anti-viral immunity. However, TNF produced by
350 CD8+ T-cells during influenza virus infection can also cause 'bystander damage' of pulmonary
351 epithelial cells, resulting in immunopathology²¹. Therefore, whether these observations contribute
352 to the increased influenza severity in individuals with diabetes with high glycaemic variability^{4,9-13}
353 remains to be determined. Nevertheless, these data provide the evidence that assessing glycaemic
354 variability may provide an important insight into the anti-viral CD8+ T-cell response of individuals
355 living with diabetes.

356 The precise mechanism by which high glycaemic variability may reduce the TNF response of CD8 T-
357 cells and affect the proportion of T_{naive} and T_{EMRA} CD8⁺ T-cells remains unclear. There is a growing
358 body of evidence that glycaemic variability is associated with increased oxidative stress and the
359 production of radical oxygen species (ROS) relative to steady state hyperglycaemia²². This may
360 directly affect T-cell function. For example, short pre-exposure of human PBMC to H₂O₂ reduces the
361 ability of activated/memory CD3⁺ and CD8⁺ T-cells (CD45RO⁺) to produce key effector cytokines such
362 as IFNγ and TNF²³. This effect may be more pronounced in activated/memory T-cells²³. Similarly,
363 over production of ROS is known to drive naïve T-cell proliferation^{24,25}. Whether these changes in
364 circulating T-cell population were the result of oxidative stress or another biological system affected
365 by glucose fluctuations in the blood remain to be determined.

366 Our study has some limitations that are important to acknowledge. Firstly, in the participant cohort
367 the sample size was low and glycaemic variability was categorized based on two weeks of CGM data.
368 Whether additional effects would have been detected if a longer period of CGM data were available
369 remains to be determined. It is also important to note that the participants recruited to this study all
370 had T1D. This patient group was selected as CGMs are more common amongst those living with T1D.
371 Interestingly, recent evidence suggests that in patients with T2D who did wear CGMs glycaemic
372 variability was associated with changes in the T cell population (namely an altered Th1/Th2 ratio and
373 frequency of Tregs)²⁶. These data suggest that the differences observed in T cell populations

374 observed herein may not be restricted to patients with T1D²⁶. Finally, additional patient information
375 such as GAD positivity or beta cell function was not recorded and may have influenced the results.

376

377 In sum, this study has provided evidence that glycaemic variability, rather than steady-state
378 hyperglycaemia, affects T cell responses to influenza virus. These data have important implications
379 for clinical practice. Specifically, these data suggest that glycaemic variability provides a possible
380 predicative approach to assess anti-viral immunity, thus providing better management of infectious
381 diseases in this patient population. Indeed, these data represent a further impetus to make CGMs
382 widely available to patients with both T1D and T2D.

383

384

385

386

387

388 **ACKNOWLEDGEMENTS**

389 We would like to thank all individuals who participated in this study. This project was supported by
390 the National Health and Medical Research Council (NHMRC; APP1159959). KRS is supported by
391 NHMRC investigator grant 2007919. CES was supported by the ARC-DECRA Fellowship
392 (#DE220100185) and the University of Melbourne Establishment Grant. KK was supported by the
393 NHMRC Leadership Investigator Grant (#1173871). EJG is supported by an Australian Research
394 Council (ARC) DECRA Fellowship (DE210101479). SG is supported by an NHMRC Senior Research
395 Fellowship (#1159272). L.C.R. is a recipient of a NHMRC EL1 Fellowship (#2026357).

396

397 The authors declare no competing interest.

398

399

400

401

402

403

404

405

406

407

408

409

410

411 **REFERENCES**

- 412 1. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza
413 illness: systematic review and meta-analysis. *Bmj* 2013; **347**.
- 414 2. Allard R, Leclerc P, Tremblay C, Tannenbaum T-N. Diabetes and the severity of pandemic
415 influenza A (H1N1) infection. *Diabetes care* 2010; **33**(7): 1491-3.
- 416 3. Longmore DK, Miller JE, Bekkering S, et al. Diabetes and overweight/obesity are
417 independent, nonadditive risk factors for in-hospital severity of COVID-19: an international,
418 multicenter retrospective meta-analysis. *Diabetes Care* 2021; **44**(6): 1281-90.
- 419 4. Zhu L, She Z-G, Cheng X, et al. Association of blood glucose control and outcomes in patients
420 with COVID-19 and pre-existing type 2 diabetes. *Cell metabolism* 2020; **31**(6): 1068-77. e3.
- 421 5. Chen Z, Liu Q, Song R, et al. The association of glycemic level and prevalence of tuberculosis:
422 a meta-analysis. *BMC Endo Dis* 2021; **21**(1): 123.
- 423 6. Charoengam N, Alexanian SM, Apovian CM, Holick MF. Association between Hyperglycemia
424 at Hospital Presentation and Hospital Outcomes in COVID-19 Patients with and without Type 2
425 Diabetes: A Retrospective Cohort Study of Hospitalized Inner-City COVID-19 Patients. *Nutrients* 2021;
426 **13**(7): 2199.
- 427 7. Hulme KD, Yan L, Marshall RJ, et al. High glucose levels increase influenza-associated damage
428 to the pulmonary epithelial-endothelial barrier. *eLife* 2020; **9**: e56907.
- 429 8. Hulme KD, Tong ZWM, Rowntree LC, et al. Increasing HbA1c is associated with reduced
430 CD8(+) T cell functionality in response to influenza virus in a TCR-dependent manner in individuals
431 with diabetes mellitus. *Cell Mol Life Sci* 2024; **81**(1): 35.
- 432 9. Marshall RJ, Armart P, Hulme KD, et al. Glycemic variability in diabetes increases the severity
433 of influenza. *MBio* 2020; **11**(2): 10.1128/mbio.02841-19.
- 434 10. Hulme KD, Gallo LA, Short KR. Influenza virus and glycemic variability in diabetes: a killer
435 combination? *Frontiers in microbiology* 2017; **8**: 264999.
- 436 11. Hartmann B, Verket M, Balfanz P, et al. Glycaemic variability is associated with all-cause
437 mortality in COVID-19 patients with ARDS, a retrospective subcohort study. *Scientific reports* 2022;
438 **12**(1): 9862.
- 439 12. Ali El Chab Parolin S, Benicio Stocco R, Kneipp Lopes JdC, et al. Association between inpatient
440 glycemic variability and COVID-19 mortality: a prospective study. *Diabetology & Metabolic Syndrome*
441 2023; **15**(1): 185.
- 442 13. Hoong CWS, Yeo XE, Lin Y, Ooi ST, Yeoh E. High glycaemic variability is associated with
443 progression of COVID-19. *Acta Diabetologica* 2021; **58**(12): 1701-4.
- 444 14. Piona C, Marigliano M, Mozzillo E, et al. Relationships between HbA1c and continuous
445 glucose monitoring metrics of glycaemic control and glucose variability in a large cohort of children
446 and adolescents with type 1 diabetes. *Diabetes Research and Clinical Practice* 2021; **177**: 108933.
- 447 15. Rama Chandran S, Tay WL, Lye WK, et al. Beyond HbA1c: Comparing Glycemic Variability and
448 Glycemic Indices in Predicting Hypoglycemia in Type 1 and Type 2 Diabetes. *Diabetes Technology &*
449 *Therapeutics* 2018; **20**(5): 353-62.
- 450 16. Van Dalem A, Demeester S, Balti EV, et al. Relationship between glycaemic variability and
451 hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes. *Diabetologia*
452 2015; **58**: 2753-64.
- 453 17. Short KR, Diavatopoulos DA, Reading PC, et al. Using bioluminescent imaging to investigate
454 synergism between *Streptococcus pneumoniae* and influenza A virus in infant mice. *J Vis Exp* 2011;
455 (50): 2357.
- 456 18. Hulme KD, Tong ZWM, Rowntree LC, et al. Increasing HbA1c is associated with reduced CD8+
457 T cell functionality in response to influenza virus in a TCR-dependent manner in individuals with
458 diabetes mellitus. *Cellular and Molecular Life Sciences* 2024; **81**(1): 35.
- 459 19. Martinez M, Santamarina J, Pavesi A, Musso C, Umpierrez GE. Glycemic variability and
460 cardiovascular disease in patients with type 2 diabetes. 2021; **9**(1): e002032.

- 461 20. Hensen L, Illing P, Clemens EB, et al. CD8+ T cell landscape in Indigenous and non-Indigenous
462 people restricted by influenza mortality-associated HLA-A*24:02 allomorph. 2021.
- 463 21. Van De Sandt CE, Bárcena M, Koster AJ, et al. Human CD8+ T cells damage noninfected
464 epithelial cells during influenza virus infection in vitro. *American Journal of Respiratory Cell and*
465 *Molecular Biology* 2017; **57**(5): 536-46.
- 466 22. Papachristoforou E, Lambadiari V, Maratou E, Makrilakis K. Association of Glycemic Indices
467 (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic
468 Complications. *J Diabetes Res* 2020; **2020**: 7489795.
- 469 23. Malmberg KJ, Arulampalam V, Ichihara F, et al. Inhibition of activated/memory (CD45RO(+))
470 T cells by oxidative stress associated with block of NF-kappaB activation. *Journal of immunology*
471 *(Baltimore, Md : 1950)* 2001; **167**(5): 2595-601.
- 472 24. Yarosz EL, Chang C-H. The Role of Reactive Oxygen Species in Regulating T Cell-mediated
473 Immunity and Disease. *Immune Netw* 2018; **18**(1).
- 474 25. Rashida Gnanaprakasam JN, Wu R, Wang R. Metabolic Reprogramming in Modulating T Cell
475 Reactive Oxygen Species Generation and Antioxidant Capacity. *Front Immunol* 2018; **9**: 1075.
- 476 26. Sun Q, Yang P, Gu Q-W, et al. Increased glycemic variability results in abnormal
477 differentiation of T cell subpopulation in type 2 diabetes patients. *Journal of Diabetes and its*
478 *Complications* 2024; **38**(6): 108738.
- 479